How I reduce and treat posttransplant relapse of MDS
Posttransplant relapse is the major cause of failure when patients undergo allogeneic stem cell transplant as a cure for myelodysplastic syndromes (MDS). M
Posttransplant relapse is the major cause of failure when patients undergo allogeneic stem cell transplant as a cure for myelodysplastic syndromes (MDS). M
Dr. Shah’s areas of expertise include immunology and immunotherapy, rare tumors, CAR T-cell therapies, and transplantation.
Research To Practice requires users to log in to view educational content. All content is available without
Patients with hematology-oncology issues require platelet transfusion support that may potentiate pulmonary injury.PRPCs decreased the probability of assis
CD19-CD28 provides effective CD28 costimulation to glofitamab-activated T cells without superagonistic properties.Triple combination with CD19–4-1BBL furth
Mediation MR analysis reveals that gut microbiota genus Ruminococcaceae UCG-002 may increase the risk of DLBCL by elevating serum MIG levels.
Retreatment with BCMA-directed therapies after prior BCMA-directed CAR-T can elicit high response rates in patients with multiple myeloma.Despite high resp
Editorial Fellowship Program | Blood | American Society of Hematology .myButton { background-color:#b7000f; border-radius:3px; border:none; display:inline-block; cursor:pointer; color:#fff!important; font-family:Arial; font-size:18px; padding:12px 24px; text-decoration:none; } .myButton:hover…
Gilead Sciences announced the discontinuation of the phase III ENHANCE-3 study, which was evaluating magrolimab in acute myeloid leukemia (AML). Additionally, the U.S. Food and…
CD33/CD123 NANOBODY TCE kills single and double-positive cells, outperforming single-targeting TCE in a subset of AML samples.CD33/CD123-TCE efficiently ki
A 60-year-old woman presented with anemia (hemoglobin, 8.7 g/dL), leukopenia (2.9 × 10 9 /L), and mild thrombocytopenia (135 × 10 9 /L). Bone marrow…